Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia.
A 58-yr-old male patient with essential thrombocythaemia (ET) developed chronic myeloid leukaemia (CML) after continuous uneventful treatment with hydroxyurea for 18 yr. G-banding analyses of bone marrow cells had repeatedly demonstrated normal male karyotype before this event, but t(9;22)(q34;q11) was demonstrated after the event. An unrelated allogeneic stem cell transplantation was performed. Blood and bone marrow morphology, and the karyotype were normalised and the patient is in good health 1 yr post-transplant. There are no previous reports in the literature about the emergence of CML during treatment with hydroxyurea.
Wahlin
Anders
A
The Department of Epidemiology, Umeå University, Umeå, Sweden. anders.wahlin@vll.se
Golovleva
Irina
I
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001856:Bone Marrow Examination; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000139:chemically induced / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D010677:Philadelphia Chromosome; D012074:Remission Induction; D013920:Thrombocythemia, Essential / Q000150:complications / Q000188:drug therapy*; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D006918:Hydroxyurea